- Home
- BRLT vs SPRB Comparison
BRLT vs SPRB Comparison
Compare BRLT & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- SPRB
- Stock Information
- Founded
- BRLT 2005
- SPRB 2014
- Country
- BRLT United States
- SPRB United States
- Employees
- BRLT N/A
- SPRB N/A
- Industry
- BRLT Consumer Specialties
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- BRLT Consumer Discretionary
- SPRB Health Care
- Exchange
- BRLT Nasdaq
- SPRB Nasdaq
- Market Cap
- BRLT 27.2M
- SPRB 22.8M
- IPO Year
- BRLT 2021
- SPRB 2020
- Fundamental
- Price
- BRLT $1.95
- SPRB $0.38
- Analyst Decision
- BRLT Buy
- SPRB Hold
- Analyst Count
- BRLT 4
- SPRB 7
- Target Price
- BRLT $3.00
- SPRB $2.17
- AVG Volume (30 Days)
- BRLT 80.0K
- SPRB 870.1K
- Earning Date
- BRLT 11-07-2024
- SPRB 11-11-2024
- Dividend Yield
- BRLT N/A
- SPRB N/A
- EPS Growth
- BRLT N/A
- SPRB N/A
- EPS
- BRLT 0.03
- SPRB N/A
- Revenue
- BRLT $426,982,000.00
- SPRB $7,101,000.00
- Revenue This Year
- BRLT N/A
- SPRB N/A
- Revenue Next Year
- BRLT $2.47
- SPRB N/A
- P/E Ratio
- BRLT $70.97
- SPRB N/A
- Revenue Growth
- BRLT N/A
- SPRB N/A
- 52 Week Low
- BRLT $1.52
- SPRB $0.37
- 52 Week High
- BRLT $3.81
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- BRLT 54.22
- SPRB 31.70
- Support Level
- BRLT $1.93
- SPRB $0.37
- Resistance Level
- BRLT $2.04
- SPRB $0.42
- Average True Range (ATR)
- BRLT 0.12
- SPRB 0.04
- MACD
- BRLT 0.00
- SPRB -0.01
- Stochastic Oscillator
- BRLT 64.86
- SPRB 5.93
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).